- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00263783
Phase I Trial of Weekly MEDI-522 in Patients With Refractory Solid Tumors
January 28, 2009 updated by: MedImmune LLC
To determine the safety profile of single and multiple doses of MEDI522 in patients with refractory solid tumors.
Study Overview
Study Type
Interventional
Enrollment
24
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Villejuf, France, 94805
- Institut Gustave Roussy
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 18 years (ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or post menopausal female patients with histologically confirmed advanced refractory solid tumors for which no reasonable therapy exists. Patient is not required to have measurable disease.
- Age >18 years
- Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 (see APPENDIX 1 for details).
- Patients who had prior surgery, radiation, or chemotherapy will be eligible provided at least 4 weeks have elapsed prior to study initiation. Patients must have recovered from treatment-related toxicities, and surgical wounds must be healed.
- Patients who have had prior immunotherapy with approved agents are eligible.
- Patients must have hemoglobin >10.0 g/dL, ANC >1,000/mm3, WBC >3,000/mm3,000/mm3, platelets ³100,000/mm3, bilirubin £2.0 mg/dL, AST/ALT no greater than 5 times the upper limit of normal (ULN), and serum creatinine <1.5 mg/dL (or calculated creatinine clearance ³60 mL/min).
- Patients must have prothrombin time (PT) and partial thromboplatin time (PTT) less than upper limit of normal or international normalized ratio (INR) less than 1.1.
- Patients must have thyroxine (T4) and thyroid-stimulating hormone (TSH) within normal limits.
- Patients must be informed of and understand the investigational nature of this trial and give written informed consent prior to receipt of any study medication or beginning study procedures.
Exclusion Criteria:
- Patient has known brain metastases or primary brain tumors, symptomatic pleural effusion or ascites requiring paracentesis.
- Patient has respiratory insufficiency requiring oxygen treatment, or has lymphangitic involvement of lungs.
- Patient has evidence of hematemesis, melena, hematochezia, or hematuria (2 or greater on urine dipstick).
- Patient has a history of a significant adverse event related to previously administered humanized monoclonal antibody.
- Patient has known HIV or hepatitis virus infection.
- Patient has prior myocardial infarction or angina, or uncontrolled hypertension (systolic BP >140 mm Hg).
- Patient has either prior strokes or transient ischemic attacks.
- Patient has active infections requiring systemic antiinfective therapy or other physical or psychological illnesses that would preclude drug administration or patient compliance.
- Patient has donated blood or received an investigational agent in the last 4 weeks.
- Patient has a history of active illness or behavior, including substance dependence or abuse that, in the opinion of the investigator, might pose additional risk in administering the study drug to the patient.
- General medical or psychological conditions that would not permit the patient to complete the study or sign the informed consent
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: 1
MEDI-522
|
MEDI-522 will be administered at doses of 1.0, 2.0, 4.0, 6.0, 8.0, and 10.0 mg/kg.
[As a 30 minute IV infusion initially as a single dose (single-dose treatment period) and 2 to 5 weeks later as weekly doses (multiple-dose treatment period) for up to 1 year.]
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety: The incidence and severity of adverse experiences and laboratory abnormalities will be tabulated and presented overall and by dose.
Time Frame: Study Day 1 up to 8 weeks
|
Study Day 1 up to 8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Pharmacokinetics: Will be assessed using the variables of area under the concentration curve (AUC) which will be calculated by the trapezoidal rule, peak concentration (Cmax), time to peak concentration (Tmax), half life
Time Frame: 35 days after the first dose
|
35 days after the first dose
|
Measured pharmacokinetic parameters may be one of the factors used in determination of the Phase II regimen.
Time Frame: Appx. 5 days after the 4th weekly dose
|
Appx. 5 days after the 4th weekly dose
|
Antitumor Activity: The antitumor activity of MEDI-522 in patients with refractory solid tumors will be assessed by calculating tumor response rate and time to disease progression.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2001
Primary Completion (ACTUAL)
April 1, 2002
Study Completion (ACTUAL)
June 1, 2002
Study Registration Dates
First Submitted
December 8, 2005
First Submitted That Met QC Criteria
December 8, 2005
First Posted (ESTIMATE)
December 9, 2005
Study Record Updates
Last Update Posted (ESTIMATE)
January 29, 2009
Last Update Submitted That Met QC Criteria
January 28, 2009
Last Verified
January 1, 2009
More Information
Terms related to this study
Other Study ID Numbers
- MI-CP065
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
University of Michigan Rogel Cancer CenterRecruitingCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
UNC Lineberger Comprehensive Cancer CenterHyundai Hope On WheelsRecruitingCancer | Pediatric Cancer | Survivorship | Cancer MetastaticUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
MiRXES Pte LtdRecruitingBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Thoracic Cancer | Liver CancerSingapore
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedGastric Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Colon Cancer | Hepatobiliary CancerUnited States
-
Johns Hopkins UniversityNational Cancer Institute (NCI); National Institute on Minority Health and...Enrolling by invitationCancer | Advanced Cancer | End Stage Cancer | MalignancyUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IV Gastric Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic Cancer | Stage IVB Colorectal Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric... and other conditionsUnited States
-
Case Comprehensive Cancer CenterCompletedStage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Stage IVA Colon Cancer | Stage IVA Rectal Cancer and other conditionsUnited States
Clinical Trials on MEDI-522
-
MedImmune LLCCompletedMalignant MelanomaUnited States
-
MedImmune LLCCompletedPsoriasisUnited States, Canada
-
MedImmune LLCCompleted
-
National Cancer Institute (NCI)TerminatedRenal Cell Carcinoma | Stage III Renal Cell Cancer | Stage IV Renal Cell Cancer | Recurrent Renal Cell CancerUnited States
-
MedImmune LLCCompletedMelanoma | Malignant Metastatic MelanomaUnited States
-
MedImmune LLCCompletedRheumatoid ArthritisUnited States, Canada
-
MedImmune LLCAstraZenecaTerminatedLupus Erythematosus, SystemicUnited States, Mexico, Peru, South Africa, Canada
-
MedImmune LLCCompletedCancer | Graft-Versus-Host DiseaseUnited States
-
MedImmune LLCTerminatedLymphoma | Leukemia | CancerUnited States
-
MedImmune LLCCompleted